What happens to your blood pressure, cholesterol, and blood sugar when you stop tirzepatide?
When you stop tirzepatide, the health improvements you gained — lower blood pressure, better cholesterol, and improved blood sugar control — tend to reverse, and the more weight you regain, the worse those markers get. In the SURMOUNT-4 trial, researchers tracked 308 people who had lost at least 10% of their body weight on tirzepatide and then stopped the drug [1]. Over the next year, those who regained less than 25% of their lost weight saw almost no change in waist circumference, non-HDL cholesterol, or fasting insulin — their health markers stayed improved. But those who regained 75% or more of their lost weight saw their systolic blood pressure rise by 10.4 mm Hg, their hemoglobin A1c (a measure of average blood sugar) increase by 0.35%, and their non-HDL cholesterol jump by 10.8% [1]. In other words, the health benefits of tirzepatide are tightly tied to keeping the weight off, and stopping the drug puts you at risk of losing those gains.
How much weight do people typically regain after stopping tirzepatide?
The vast majority of people regain a significant amount of weight after stopping tirzepatide, and the regain happens quickly. In the SURMOUNT-4 trial, after 36 weeks on tirzepatide and then switching to placebo for 52 weeks, the average weight regain was 14.0% of body weight — meaning people gained back most of what they had lost [5]. Only 16.6% of those who stopped the drug maintained at least 80% of their weight loss, compared with 89.5% of those who kept taking tirzepatide [5]. A real-world study of 68 patients found that 72% regained more than 10% of their lost weight within just 5 months of stopping, and by 9 months, the average regain was 45% of the weight they had lost [3]. The more weight you lost on tirzepatide, the more you tended to regain after stopping — a pattern the researchers called a strong predictor of weight regain [3].
Is there any health benefit that persists after stopping tirzepatide?
The evidence suggests that if you manage to keep off most of the weight you lost — for example, regaining less than 25% of it — some health improvements can persist. In the SURMOUNT-4 analysis, people in that minimal-regain group showed no significant worsening of waist circumference, non-HDL cholesterol, or fasting insulin a year after stopping the drug [1]. Their blood pressure and blood sugar did rise slightly, but much less than in people who regained more weight [1]. However, this group was small — only 54 out of 308 participants — and the study did not identify a reliable way to predict who would be able to maintain that level of weight loss without the drug [1]. For the vast majority, stopping tirzepatide leads to substantial weight regain and a corresponding loss of the cardiometabolic benefits.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 3 from 2024 or later, 5 in Q1 journals, collectively cited 3,867 times — selected as the most relevant from 8 studies that passed quality screening, drawn from 40 papers retrieved from a database of over 500 million.
Sources used in this answer
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity
In a post hoc analysis of the SURMOUNT-4 trial (308 participants), those who regained more weight after stopping tirzepatide had larger reversals of improvements in waist circumference, systolic blood pressure, non-HDL cholesterol, hemoglobin A1c, and fasting insulin; those who regained less than 25% of lost weight maintained most benefits.
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
In a randomized controlled trial of 731 patients with heart failure with preserved ejection fraction and obesity, tirzepatide reduced the risk of cardiovascular death or worsening heart failure by 38% compared with placebo and improved quality of life scores.
1757-P: The Rebound Effect—Weight Regain after Tirzepatide Discontinuation
In a real-world retrospective study of 68 patients, 72% regained more than 10% of lost weight within 5 months of stopping tirzepatide, and greater weight loss before discontinuation was the only predictor of greater regain.
Tirzepatide Once Weekly for the Treatment of Obesity
In the SURMOUNT-1 trial (2,539 participants with obesity), tirzepatide 15 mg led to an average 20.9% weight loss at 72 weeks, with 91% of participants losing at least 5% of body weight.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
In the SURMOUNT-4 randomized withdrawal trial (670 participants), those who continued tirzepatide maintained an average 25.3% weight loss from baseline at 88 weeks, while those switched to placebo regained 14.0% of body weight and only 16.6% maintained at least 80% of their initial loss.